Search

Hikma Pharmaceuticals PLC

Avatud

SektorTervishoid

1,912

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1905

Max

1928

Põhinäitajad

By Trading Economics

Sissetulek

-93M

133M

Müük

-11M

1.6B

P/E

Sektori keskmine

15.451

57.333

Aktsiakasum

1.27

Dividenditootlus

3.24

Kasumimarginaal

8.537

Töötajad

9,500

EBITDA

-211M

288M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+27.23% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.24%

2.63%

Turustatistika

By TradingEconomics

Turukapital

-930M

4.2B

Eelmine avamishind

1912

Eelmine sulgemishind

1912

Hikma Pharmaceuticals PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. apr 2025, 08:20 UTC

Market Talk

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

Hikma Pharmaceuticals PLC Prognoos

Hinnasiht

By TipRanks

27.23% tõus

12 kuu keskmine prognoos

Keskmine 2,422.5 GBX  27.23%

Kõrge 2,650 GBX

Madal 2,000 GBX

Põhineb 7 Wall Streeti analüütiku instrumendi Hikma Pharmaceuticals PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

5

Osta

2

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.